Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Treatment of Mandibular Overjet in Children With Maxillary Retrognathism

NCT07706400 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2026-07-31
Last updated
2026-07-15

Condition(s) studied

Maxillary RetrognathismChildrenTreatmentClass III Malocclusion

Investigational drug(s) / intervention(s)

Interceptive treatment

Interceptive treatment: Control

Study summary

The project involves a 10-year prospective longitudinal cohort multicentre study where orthodontic treatment and treatment effect is followed in children with Cl III due to maxillary retrognathia who undergo standardized orthodontic interceptive treatment. Standard clinical procedures are followed as usual at each clinic where standard diagnostic and follow up materials are taken before treatment, after treatment and follow ups after 5 and 10 years. The project will not introduce or test new treatment modalities, additional procedures or behavioural regulation in relation to normal clinical practice or new medical devices. The standard diagnostic and follow up materials in each clinic include examination of the dentition, occlusion, craniofacial morphology, and orofacial function. The analyses are based on the following standardized registration methods which are carried out on all the patients. Information from the patient record is included.

The patient related outcome measurements will be assessed by five different questionnaires. No biological material is collected for the project.

Eligibility

Sex
ALL
Min age
9 Years
Max age
12 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Mandibular overjet due to maxillary retrognathia (Overjet \</= 0 mm) * Age 9-12 years * Informed consent from parents/guardians Exclusion Criteria: * Mandibular overjet mainly due to mandibular prognathism * Known general and/or craniofacial syndromes/diseases * Adenoid vegetations, hypertrophic tonsils and significantly reduced air passage through nose (mouth breathing), which must be primarily treated * Functional disorders in muscles and jaw joints, which must be primarily treated

Primary outcome measure(s)

  • Change in sagittal maxillary skeletal position — Baseline (mixed dentition) to young adulthood, up to 10 years.
    Sagittal maxillary skeletal position will be assessed using standardized lateral cephalometric radiographs. Cephalometric measurements reflecting anterior (mesial) displacement of the maxilla will be obtained at baseline during the mixed dentition stage and at follow-up in young adulthood. Changes in maxillary position will be compared among participants receiving different interceptive orthodontic treatments and untreated controls.

Trial sites (3)

FacilityCityRegionStatus
University of Copenhagen Copenhagen Denmark
Faculty of Odontology Malmö Skåne County
Malmö University Malmö Skåne County
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07706400 on ClinicalTrials.gov ↗ ← All trials in Denmark